Ouro Medicines Launches OM336 Trial for Autoimmune Cytopenias
June 12, 2025
In an investigator-sponsored study of OM336, two patients with relapsed/refractory autoimmune hemolytic anemia showed rapid and sustained remissions out to month six, without other immunosuppressive